Lincoln Pharmaceuticals Ltd
Lincoln Pharmaceuticals Limited (LPL) is engaged in the business of manufacturing, marketing and distribution of pharmaceutical products.
- Market Cap ₹ 569 Cr.
- Current Price ₹ 284
- High / Low ₹ 415 / 275
- Stock P/E 8.20
- Book Value ₹ 216
- Dividend Yield 0.53 %
- ROCE 24.0 %
- ROE 17.2 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- The company has delivered a poor sales growth of 5.56% over past five years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
176 | 188 | 195 | 210 | 266 | 400 | 360 | 361 | 366 | 386 | 424 | 472 | |
167 | 174 | 179 | 190 | 240 | 359 | 313 | 308 | 299 | 321 | 337 | 377 | |
Operating Profit | 10 | 14 | 16 | 20 | 26 | 41 | 47 | 53 | 68 | 66 | 87 | 95 |
OPM % | 5% | 7% | 8% | 10% | 10% | 10% | 13% | 15% | 18% | 17% | 21% | 20% |
3 | 3 | 6 | 2 | 7 | 7 | 2 | 5 | 5 | 11 | 5 | 10 | |
Interest | 5 | 8 | 8 | 7 | 8 | 10 | 7 | 5 | 4 | 2 | 2 | 1 |
Depreciation | 2 | 2 | 3 | 4 | 5 | 5 | 6 | 6 | 7 | 7 | 8 | 8 |
Profit before tax | 6 | 7 | 11 | 12 | 20 | 33 | 37 | 46 | 62 | 67 | 84 | 96 |
Tax % | 33% | 30% | 16% | 16% | 24% | 28% | 25% | 25% | 22% | 23% | 26% | 28% |
Net Profit | 4 | 5 | 10 | 11 | 15 | 24 | 28 | 35 | 49 | 51 | 62 | 69 |
EPS in Rs | 2.56 | 3.14 | 5.92 | 6.53 | 9.20 | 14.52 | 14.06 | 17.31 | 24.36 | 25.72 | 31.11 | 34.63 |
Dividend Payout % | 23% | 19% | 10% | 9% | 11% | 7% | 9% | 9% | 6% | 6% | 5% | 4% |
Compounded Sales Growth | |
---|---|
10 Years: | 10% |
5 Years: | 6% |
3 Years: | 9% |
TTM: | 11% |
Compounded Profit Growth | |
---|---|
10 Years: | 32% |
5 Years: | 20% |
3 Years: | 12% |
TTM: | 11% |
Stock Price CAGR | |
---|---|
10 Years: | 26% |
5 Years: | 7% |
3 Years: | 15% |
1 Year: | -13% |
Return on Equity | |
---|---|
10 Years: | 17% |
5 Years: | 18% |
3 Years: | 18% |
Last Year: | 17% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
16 | 16 | 16 | 16 | 16 | 16 | 20 | 20 | 20 | 20 | 20 | 20 | |
Reserves | 60 | 64 | 73 | 82 | 95 | 117 | 172 | 204 | 249 | 293 | 355 | 413 |
Borrowings | 44 | 65 | 76 | 68 | 76 | 78 | 64 | 61 | 34 | 5 | 1 | 2 |
44 | 66 | 72 | 93 | 70 | 64 | 48 | 62 | 63 | 71 | 84 | 99 | |
Total Liabilities | 165 | 212 | 237 | 260 | 258 | 275 | 305 | 347 | 366 | 389 | 459 | 534 |
28 | 38 | 65 | 65 | 66 | 98 | 103 | 117 | 121 | 123 | 120 | 132 | |
CWIP | 4 | 14 | 2 | 2 | 3 | 3 | 7 | 0 | 2 | 0 | 2 | 16 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 10 | 11 | 18 | 34 | 81 | 97 |
133 | 161 | 169 | 192 | 190 | 174 | 186 | 219 | 225 | 232 | 257 | 290 | |
Total Assets | 165 | 212 | 237 | 260 | 258 | 275 | 305 | 347 | 366 | 389 | 459 | 534 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-34 | 12 | -16 | 5 | 25 | 45 | 25 | 27 | 53 | 75 | 69 | 76 | |
-11 | -27 | -16 | 1 | 7 | -42 | -25 | -12 | -18 | -31 | -64 | -78 | |
45 | 16 | 29 | -11 | -32 | -3 | 0 | -11 | -36 | -38 | -6 | -3 | |
Net Cash Flow | -0 | 1 | -3 | -4 | -1 | -0 | -0 | 3 | -1 | 7 | -1 | -4 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 83 | 127 | 140 | 154 | 163 | 73 | 92 | 111 | 122 | 96 | 96 | 90 |
Inventory Days | 90 | 64 | 54 | 62 | 44 | 36 | 63 | 86 | 75 | 95 | 86 | 121 |
Days Payable | 78 | 125 | 133 | 174 | 92 | 40 | 54 | 82 | 92 | 102 | 105 | 120 |
Cash Conversion Cycle | 95 | 66 | 62 | 43 | 116 | 70 | 100 | 115 | 106 | 88 | 77 | 91 |
Working Capital Days | 144 | 99 | 91 | 98 | 146 | 81 | 122 | 144 | 145 | 130 | 119 | 188 |
ROCE % | 10% | 10% | 11% | 12% | 16% | 22% | 19% | 19% | 23% | 22% | 25% | 24% |
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
1d - From time to time and SEBI Circular No. CIR/CFD/CMDl/27/2019 dated February 08, 2019, we enclosed herewith the annual secretarial compliance report as issued by M/s. …
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2d - Copies of published newspaper advertisement with respect to the audited financial results (standalone and consolidated) of the Company for the quarter and year ended March …
- Financial Result For The Quarter And Year Ended March 31, 2022 2d
- Board recommends Dividend 2d
- Board Meeting Outcome for Outcome Of The Board Meeting 2d
Annual reports
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Revenue mix
Domestic sales: 164 Cr. in FY21 vs 168 Cr. in FY20
Exports: 261 Cr. in FY21 vs 218 Cr. in FY20
Focus of the company shifted from domestic contract manufacturing business to exports business in FY17 leading to higher margins in recent years.